GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study In this pilot study, we assessed the adoptive T-cell ...
Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...
A dealership's rating is based on all of their reviews, with more weight given to recent reviews. Want to share your experience with this dealership? Everyone was helpful and friendly. It was a ...
Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.
SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his “free the ...
Key stocks in focus include General Insurance Corp, ONGC, SpiceJet, GSK Pharma, and Cipla due to various developments. Notable updates include the government's stake sale in General Insurance Corp and ...
The net deficit of the GSK Group’s defined benefit (DB) pension scheme increased from £1,129m at 31 December 2021 to £1,355m as at 31 December 2022, despite an increase in cash contributions from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback